Clinical trial Recruiting at 1 site Interventional Ages 18 to 80 Women only

Advanced imaging to improve breast cancer diagnosis and treatment decisions

Official title: The Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer

Run by Yunnan Cancer Hospital · NCT07608081 · Data updated 2026-11-12

This study tests whether multiple advanced MRI techniques can more accurately diagnose breast cancer and help tailor treatment for women with suspicious breast lesions.

More Breast Cancer trials

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexWomen only
Enrollment1000 (estimated)
SponsorYunnan Cancer Hospital
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Kunming, Yunnan)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedOctober 1, 2027
Study endsOctober 1, 2027
Registry record updatedMay 27, 2026
Trial IDNCT07608081 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18 or older with BI-RADS 4 or higher breast lesions who can undergo the specified MRI examinations within one week before biopsy or surgery.

Probably not a fit

Patients whose lesions are clearly benign on standard imaging or who cannot complete MRI procedures may see limited benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial enrolls adult women with BI-RADS 4 or higher breast lesions and uses ultrafast DCE-MRI, time-dependent diffusion MRI, MR elastography, and virtual MR elastography before biopsy or surgery to collect imaging and clinical data. Researchers will analyze how these imaging modalities together may improve precision in diagnosis, treatment planning, and prognosis. The study aims to create a robust imaging basis to guide individualized care and potentially improve outcomes and resource use.

Why it matters

Potential benefit: If successful, patients may receive more accurate diagnoses and more precisely targeted treatment plans.

How similar studies have gone: Multimodal MRI approaches have shown promise in improving characterization of breast lesions, but this exact combination is relatively novel and exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years old
2. Female patients with BI-RADS class 4 or above breast lesions detected by mammography or ultrasound
3. Perform breast new technology MRI examination (ultra fast DCE-MRI、OGSE 、MRE、vMRE)within one week before biopsy or surgery

Exclusion Criteria:

1. Previously received breast radiotherapy, chemotherapy, surgery, or targeted therapy
2. Unable to cooperate in completing MRI examination
3. The image data contains serious artifacts (such as motion artifacts and metal artifacts), making it impossible to measure parameters
4. The lesion cannot be clearly identified and outlined on the image
5. Pregnant and lactating women
6. Combined with severe liver, liver, and kidney diseases, coagulation dysfunction, or other malignant tumors

Where it's running

  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.